BSX
HealthcareBoston Scientific Corporation · Medical - Devices · $63B
What is Boston Scientific Corporation?
Boston Scientific Corporation is a global medical device company serving interventional medicine across cardiology, urology, neurology, and gastroenterology. Founded in 1992 and headquartered in Marlborough, Massachusetts, it sells products in markets worldwide.
Boston Scientific develops and manufactures devices used by physicians to diagnose and treat conditions without traditional open surgery. Its three segments — MedSurg, Rhythm and Neuro, and Cardiovascular — cover a wide range of clinical needs. Revenue comes from selling capital equipment, single-use consumables, and implantable devices to hospitals and specialty clinics. The company competes on clinical outcomes, device innovation, and deep relationships with interventional specialists.
Boston Scientific was founded in 1992 and is headquartered in Marlborough, Massachusetts.
- Drug-eluting coronary stent systems for coronary artery disease treatment
- Implantable cardiac defibrillators and resynchronization therapy devices
- 3-D cardiac mapping and ablation catheter systems
- Spinal cord and deep brain stimulation systems for chronic pain and neurological conditions
- Devices for gastrointestinal, urological, and pulmonary interventions
Is BSX a Good Stock to Buy?
UQS Score rates BSX as Good overall, reflecting a balanced profile across its five analytical pillars.
The Growth pillar stands out as a relative strength, supported by Boston Scientific's expanding product portfolio and continued penetration into high-demand interventional markets. The Valuation pillar also registers as Good, suggesting the market's current pricing is not extreme relative to the company's fundamental profile.
The Quality, Moat, and Risk pillars each land at Neutral, indicating that while the business is operationally capable, its competitive durability and financial efficiency are not yet among the strongest in the large-cap healthcare device space.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BSX pay dividends?
No — Boston Scientific Corporation does not currently pay a dividend.
Boston Scientific does not currently pay a dividend. For a capital-intensive medical device company in an active growth phase, this is common — management typically reinvests cash into research and development, clinical trials, and acquisitions rather than returning capital to shareholders through distributions. Income-focused investors should factor this into their portfolio planning.
When does BSX report earnings?
Boston Scientific reports earnings on a quarterly cadence, consistent with standard practice for US-listed large-cap equities.
The company's Growth pillar rating reflects a track record of expanding revenues across its core segments. Cardiovascular and Rhythm and Neuro have been particularly active areas, driven by new product launches and procedure volume recovery in hospitals globally.
For the most recent quarter's results and guidance updates, visit Boston Scientific's official investor relations page.
BSX Price History
+2.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Boston Scientific Corporation?
Based on Boston Scientific Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
BSX Long-term Outlook
Boston Scientific's Good Growth pillar suggests the company is on a trajectory of above-average expansion relative to the broader healthcare sector. Its Neutral Risk pillar indicates a manageable but not negligible set of operational and regulatory exposures. The Good Valuation pillar means the stock does not appear to be pricing in excessive optimism, leaving room for the growth story to develop without requiring a perfect execution record.
Growth drivers
- Continued adoption of minimally invasive cardiovascular and electrophysiology procedures globally
- New product launches across structural heart, neuromodulation, and urology segments
- Geographic expansion into underpenetrated international markets
Key risks
- Regulatory approval delays or product recalls affecting device commercialization timelines
- Pricing pressure from hospital procurement consolidation and reimbursement changes
- Integration risk from acquisitions that are central to the company's growth strategy
BSX vs Peers
Boston Scientific operates in a competitive large-cap medical device landscape alongside several diversified peers.
Medtronic is a larger, more diversified device conglomerate with a broader geographic footprint and a longer dividend history than Boston Scientific.
Stryker focuses more heavily on orthopedics and surgical equipment, giving it a different end-market mix compared to Boston Scientific's cardiovascular and neuro emphasis.
Abbott competes directly in structural heart and electrophysiology but also operates diagnostics and nutrition businesses, making it a more diversified healthcare conglomerate.
Frequently Asked Questions
What does Boston Scientific do?
Boston Scientific develops and sells medical devices used in minimally invasive procedures across cardiology, electrophysiology, urology, gastroenterology, and neurology. Its products are used in hospitals and specialty clinics worldwide. The company operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular.
Does BSX pay dividends?
No, Boston Scientific does not currently pay a dividend. The company reinvests its cash flow into research and development, product innovation, and acquisitions. Investors seeking income from their healthcare holdings may want to consider this when evaluating BSX.
When does BSX report earnings?
Boston Scientific reports financial results on a quarterly basis, in line with standard US-listed company practice. For exact dates and the most recent earnings releases, check the investor relations section of the Boston Scientific corporate website.
Is BSX a good stock to buy?
UQS Score rates BSX as Good overall. Its Growth and Valuation pillars are relative strengths, while Quality, Moat, and Risk are each Neutral. Whether it fits your portfolio depends on your investment goals — the full pillar breakdown is available to UQS Pro members.
Is BSX overvalued?
The UQS Valuation pillar for BSX is rated Good, suggesting the stock is not priced at an extreme premium relative to its fundamental profile. That said, valuation is one of five pillars — viewing it alongside Growth and Risk provides a more complete picture.
How does BSX compare to its competitors?
Boston Scientific sits alongside Medtronic, Stryker, and Abbott in the large-cap medical device space. Each competitor has a different product mix and business model emphasis. UQS Pro members can view side-by-side pillar comparisons to see how BSX stacks up quantitatively.
What is BSX's market cap bracket?
Boston Scientific is classified as a large-cap company. This places it among the more established, widely followed names in the healthcare and medical device sector, typically with greater institutional ownership and analyst coverage than smaller peers.
Who founded Boston Scientific?
Boston Scientific was founded in 1992. Information on the company's founders is widely available through public sources, including the company's own corporate history page and major financial reference sites.
Is BSX a long-term quality investment?
As a long-term quality indicator, BSX's Good UQS Score reflects a business with meaningful growth momentum and reasonable valuation, tempered by Neutral ratings on Quality, Moat, and Risk. Long-term investors should weigh the full pillar profile, available in detail for UQS Pro members.
What is the main competitive advantage of Boston Scientific?
Boston Scientific's competitive position rests on its broad device portfolio, deep clinical relationships with interventional specialists, and ongoing investment in next-generation technologies. Its presence across multiple high-growth procedure categories provides some diversification within the medical device market.
What sector does BSX belong to?
Boston Scientific belongs to the Healthcare sector, specifically within the medical devices and equipment industry. It is one of the larger pure-play medical device companies listed on US exchanges, focused on interventional and minimally invasive procedures.
Is BSX a growth stock or value stock?
Based on its UQS pillar profile, BSX leans toward the growth side — its Growth pillar is rated Good, while its Valuation pillar is also Good rather than Attractive. This positions it as a growth-oriented name that is not trading at a deep discount, but also not at an extreme premium.
Unlock Full BSX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access complete financial metrics and trend data
- ✓Compare BSX side-by-side with MDT, SYK, and ABT
- ✓See valuation context versus large-cap healthcare peers
- ✓Get the full risk and quality breakdown in one view
- ✓Track score changes as new earnings data is released
Pro Analysis
BSX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Oct 4, 2026 | 17.3 | 0.0 | 47.0 | 0.0 | 36.9 | 0.0 | -43.3 |
| Jul 30, 2026 | 60.6 | 67.8 | 47.0 | 70.1 | 44.2 | 75.1 | -3.0 |
| Jul 27, 2026 | 63.6 | 66.3 | 47.0 | 70.1 | 60.7 | 80.8 | +0.3 |
| Jul 25, 2026 | 63.3 | 66.3 | 47.0 | 70.1 | 60.7 | 79.0 | -0.1 |
| Jul 24, 2026 | 63.4 | 66.4 | 47.0 | 70.1 | 60.7 | 79.8 | -0.2 |
| Jul 22, 2026 | 63.6 | 66.5 | 47.0 | 70.1 | 60.7 | 80.4 | +0.1 |
| Jul 21, 2026 | 63.5 | 66.4 | 47.0 | 70.1 | 60.7 | 80.3 | 0.0 |
| Jul 20, 2026 | 63.5 | 66.3 | 47.0 | 70.1 | 60.7 | 80.1 | +0.1 |
| Jul 18, 2026 | 63.4 | 66.3 | 47.0 | 70.0 | 60.7 | 80.0 | 0.0 |
| Jul 17, 2026 | 63.4 | 66.2 | 47.0 | 70.0 | 60.7 | 79.8 | -0.3 |
BSX — Pillar Breakdown
Quality
— 0.0/100 (25%)Boston Scientific Corporation currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Ability to convert revenue into operating profit.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Boston Scientific Corporation faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Analyst consensus for future revenue growth.
Risk
— 36.9/100 (15%)Boston Scientific Corporation has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Boston Scientific Corporation appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 47/100 (25%)Boston Scientific Corporation possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BSX.
Score Composition
Financial Data
More Stock Analysis
How is the BSX UQS Score Calculated?
The UQS (Unified Quality Score) for Boston Scientific Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Boston Scientific Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Boston Scientific Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.